Choroidal Neovascularization Clinical Trial
Official title:
Biomarkers Analysis of Mineralocortoid Receptor Activation in the Serum and Ocular Fluid of Patients With Choroidal Neovascularization
The aim of the study is to find biomarkers in the blood and aqueous humor of patients with type 1 choroidal neovascularization and correlate them with the response to anti-VEGF treatment.
Age-related macular degeneration (AMD) is the most frequent cause of blindness in
industrialized countries. Multiple molecular pathways have been implicated in the
pathogenesis of choroidal neovascularization (CNV). Currently, the treatment relies on
neutralization of VEGF (Vascular Endothelial Growth Factor). However some patients have an
incomplete response to anti-VEGF treatment. A recent study suggested the implication of the
mineralocorticoid receptor pathway in the formation of CNV.
The study (of investigators) aim is to evaluate the concentation of metabolites of MR pathway
in the blood and aqueous humor of patients with CNV and compared them with patients without
CNV in order to increase our understanding of CNV pathogenesis and find potential biomarker
of response to anti-VEGF treatment.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01908816 -
An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.
|
Phase 3 | |
| Completed |
NCT02015351 -
Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study
|
N/A | |
| Withdrawn |
NCT01666236 -
Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy
|
Phase 4 | |
| Completed |
NCT01175395 -
20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
| Terminated |
NCT00712491 -
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
| Completed |
NCT00533520 -
Evaluation of Dosing Interval of Higher Doses of Ranibizumab
|
Phase 4 | |
| Completed |
NCT00242580 -
A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
|
Phase 3 | |
| Completed |
NCT04075188 -
Treatment of Polypoidal Choroidal Vasculopathy in Pachychoroid
|
N/A | |
| Not yet recruiting |
NCT05055973 -
OCTA Insights in CNVM, Morphological Characteristics and Correlation With Structural OCT.
|
||
| Recruiting |
NCT00568191 -
Stratus Versus Cirrus OCT in AMD
|
N/A | |
| Completed |
NCT01256632 -
Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy
|
N/A | |
| Recruiting |
NCT00100087 -
Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System
|
Phase 1/Phase 2 | |
| Completed |
NCT04455399 -
Time Efficiency Comparison of Two IntraVitreal Injection Techniques
|
N/A | |
| Terminated |
NCT02857894 -
Genetic Factors of Idiopathic Polypoidal Vasculopathies in the ATM Gene (Ataxia Telangiectasia Mutated)
|
||
| Not yet recruiting |
NCT02934841 -
Conbercept in Choroidal Neovascularization Secondary to Uveitis
|
Phase 2 | |
| Completed |
NCT01880788 -
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
|
N/A | |
| Completed |
NCT00775411 -
Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)
|
Phase 2 | |
| Completed |
NCT00604071 -
Sensitivity of the Home Macular Perimeter (HMP)
|
N/A | |
| Completed |
NCT00406250 -
Intravitreal Bevacizumab in Agioid Streaks
|
Phase 1 | |
| Withdrawn |
NCT00403156 -
Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
|
Phase 1 |